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Abstract:  Cardiovascular  disease  [CVD]  is  a  leading  cause  of  mortality  accounting  for  a  global  incidence  of  over  31%.
Atherosclerosis is the primary pathophysiology underpinning most types of CVD. Historically, modifiable and non-modifiable risk
factors  were  suggested  to  precipitate  CVD.  Recently,  epidemiological  studies  have  identified  emerging  risk  factors  including
hypotestosteronaemia,  which  have  been  associated  with  CVD.  Previously  considered  in  the  realms  of  reproductive  biology,
testosterone is now believed to play a critical role in the cardiovascular system in health and disease. The actions of testosterone as
they relate to the cardiac vasculature and its implication in cardiovascular pathology is reviewed.
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1. INTRODUCTION
Cardiovascular disease [CVD] is the leading cause of mortality globally. It was responsible for an estimated 17.5
million deaths in 2012, which accounted for 31% of the global crude death rate [1].
CVDs primarily affect the cardiac parenchyma or vasculature [2]. They are precipitated by non-modifiable as well
as  modifiable  risk  factors.  Emerging  risk  factors,  such  as  hypotestosteronaemia  have  recently  been  suggested  to
contribute to the pathogenesis [3, 4].
The  majority  of  CVD  aetiologies  can  be  attributed  to  atherosclerosis.  Atherosclerosis,  a  specific  type  of
arteriosclerosis,  which  is  characterised  by  lipid  accumulation  and  mononuclear  leukocyte  infiltration  in  the  tunica
intima of vessels, results in mural thickening [5]. Although the exact mechanisms are not fully understood, in most
cases  oxidised  LDL [oxLDL]  is  often  considered  the  culprit  since  it  is  believed  to  trigger  a  chronic  inflammatory
response  [6,  7].  The  corollary  is  monocyte  and  T-cell  recruitment  to  the  ‘site  of  injury’,  where  monocytes  are
subsequently  transformed  into  lipid-laden  macrophages  foam  cells  along  with  smooth  muscle  cells  [SMCs]  and
fibroblasts [8].
Eventually, atheromatous plaque formation occurs and later devlops a necrotic core and fibrous cap [8]. Luminal
stenosis  consequently  limits  perfusion.  Complications  of  atheroma  include  plaque  rupture  and  resultant
thromboembolism, plaque fissure, and plaque ulceration [9, 10]. Acute coronary syndromes [ACS] namely ischaemic
stroke, unstable angina and myocardial infarction are also sequlae [9, 11, 12].
In  2009  the  total  cost  of  CVD  per  capita  from  all  European  Union  member  states  was  €212,  9%  of  the  total
healthcare expenditure [13]. CVD is therefore a pressing public health issue.
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2. TESTOSTERONE AND THE CARDIOVASCULAR SYSTEM
2.1. Testosterone Physiology
Testosterone  is  an  androgen  steroid  hormone  derived  from  cholesterol  [14].  It  circulates  in  two  major  forms:
dehydroepiandrosterone  sulphate  [DHEA-S]  and  androstenedione  [AS]  [15].  Synthesis  of  testosterone  and  5a-
dihydrotestosterone [5a-DHT] occurs primarily in the Leydig cells in the testis [15]. Peripheral sites of synthesis include
the zona reticularis of the adrenal cortex [DHEA-S and AS] in both sexes, and skin [testosterone and 5α-DHT] to a
lesser extent [15, 16]. Testosterone production also occurs in females from Graafian follicle theca interna cells in the
form  of  AS,  the  majority  of  which  is  converted  to  17β-estradiol  by  the  enzyme  aromatase  [17,  18].  Peripheral
testosterone  production  is  regulated  by  hypothalamic  gonadotrophin-releasing  hormone  [GnRH]  and  the  anterior
pituitary hormone adrenocorticotropin horomone [ACTH] [16, 19]. On the other hand, gonadal synthesis is governed by
GnRH and luteinising hormone [LH] [19, 20]. In both instances, feedback loops exist to ensure adequate regulation of
the hypothalamic-pituitary-gonadal [HPG] axis as well as the hypothalamic-pituitary-adrenal [HPA] axis [21, 22].
2.2. Classical Functions
Testosterone acts via the androgen receptor [AR] to mediate an extensive array of physiological processes [23].
Primarily,  testosterone  is  a  sex  hormone  that  determines  and  regulates  the  development  of  male  secondary  sexual
characteristics  [24].  It  increases  libido  and  improves  erectile  function,  but  also  has  a  number  of  anabolic  roles.
Testosterone stimulates nitrogen retention by increasing the rate of protein synthesis and decreasing the rate of protein
catabolism. It is therefore responsible for increasing muscle mass [25]. In addition, testosterone indirectly inhibits bone
resorption through its conversion to estradiol [26]. DHT directly stimulates osteoblastic activity and bone growth [27].
In  addition  to  these  classical  functions,  testosterone  is  also  responsible  for  mediating  other  crucial  physiological
processes.
2.3. Non Classical Functions
Testosterone is seldom affiliated with the circulatory system, if at all. Its role as a promoter of erythropoiesis has not
extensively been discussed [28]. In fact, an elevated haematocrit is a side effect associated with administration of acute
supraphysiological  concentrations  of  testosterone  [29].  Furthermore,  testosterone  has  been  implicated  in  cerebral
physiology, though this is not without controversy. Testosterone has been shown to improve cerebral perfusion and thus
mood in hypogonadal men [30, 31]. Some investigators even go as far as stating that testosterone plays significant roles
in memory, strategic planning, higher order motor actions, as well as cognitive and emotional behaviours [24].
2.4. Testosterone and Cardiac Vasculature
2.4.1. Epidemiology
Hypogonadism, as defined by The Endocrine Society’s Clinical  Practice Guideline for Testosterone Therapy in
Adult  Men  with  Androgen  Deficiency  Syndromes,  is  “a  clinical  syndrome that  results  from failure  of  the  testis  to
produce physiological levels of testosterone [androgen deficiency] and a normal number of spermatozoa caused by a
disruption  of  one  or  more  levels  of  the  hypothalamic-pituitary-gonadal  [HPG]  axis”  [32].  The  normal  testosterone
laboratory reference range is 10.4 – 34.7 nmol/L [300 – 1000 ng/dL] [33]. Epidemiological studies have associated low
testosterone levels with all-cause mortality and an increased risk of CVD, both of which were statistically significant [4,
34 - 36]. The association with increased risk of CVD persists even when corrected for age, as testosterone levels are
known to increase at approximately age 30, and thereafter decrease with an increase in age [37 - 39]. In fact, a case
control study conducted over a  7 year period, consisting of  2314 men aged  40-79 years, found that  every 173 ng/dL
[6 nmol/L] increase in serum testosterone was associated with a 21% lower risk of all-cause mortality after correcting
for age, body mass index, systolic blood pressure, cholesterol,  cigarette smoking, diabetes, alcohol intake, physical
activity, social class, education, and sex hormone-binding globulin [35].
While some investigators have linked hypogonadism to an increased risk of coronary artery disease [CAD] others
have failed to replicate this association [4, 40]. This discrepancy could be due to differences in study design. Some
investigators  failed  to  account  for  the  subfraction  of  testosterone  utilised  and the  serum quantification  method [4].
Testosterone circulates in blood as bioavailable and bound testosterone, and both these subfractions constitute total
testosterone  [4].  Bioavailable  testosterone  makes  up  approximately  33% of  circulating  testosterone,  30% of  which
circulates bound to albumin and 1-3% free in blood [4]. On the other hand, the bound testosterone fraction circulates in
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blood bound to Sex Hormone Binding Globulin [SHBG] and is responsible for 68% of circulating testosterone [4].
Testosterone  Replacement  Therapy  [TRT]  serves  to  substantiate  the  importance  of  testosterone  in  the  cardiac
vasculature in health and disease (Fig. 1). Three randomised placebo-controlled trials have shown myocardial ischaemia
improvement in men with CAD, due to an extension of time to exercise-induced ST-segment depression, as measured
on treadmill exercise stress test [41 - 43]. Moreover, to the best of our knowledge, there is currently no published study
in the literature demonstrating a statistically significant association between TRT and cardiovascular adverse events in a
large cohort.
Fig. (1). Summary diagram of the key roles of testosterone in cardiovascular system.
Most of the negative connotations attributed to the effects of androgens on the cardiovascular system stem from the
observational  link  established  between  sudden  death  and  androgen  abuse  in  athletes  [24,  38].  To  the  best  of  our
knowledge, there is no study in the scientific literature presenting statistically significant data to support a causative role
for anabolic androgens in cardiovascular adverse events in athletes. In this context, perhaps the chronic administration
of anabolic androgens at supraphysiological rather than physiological levels leads to toxicity and death, though robust
studies are needed to substantiate this.
2.4.2. Vasodilation
Testosterone is essential for normal healthy vascular function [4]. The consensus from animal studies points to its
role in vasodilation [38, 44]. Deenadayalu et al.  conducted a study in pre-contracted swine left anterior descending
coronary arteries [LAD] where prostaglandin served as the contractile agent. The effects of endothelial denudation and
either Krebs-Henseleit  Bicarbonate [KHB] solution, or N-nitro-L-arginine methyl ester [L-NAME] on testosterone-
treated  vessels  were  tested.  KHB is  a  well-known  physiological  buffer  whereas  L-NAME antagonises  the  enzyme
responsible for nitric oxide production, nitric oxide synthase [NOS]. An increase in vascular relaxation percentage and
vasodilatation was observed following testosterone administration in a dose-dependent fashion. This effect was not
blunted by vascular denudation nor administration of L-NAME and KHB [44, 45]
There is ample evidence in the scientific literature on the vasodilatory effects of testosterone on the vascular system,
though little is known about the mechanisms through which testosterone exerts this effect. It has been suggested that
testosterone may trigger vasodilatation via endothelial-independent non-genomic means, given its rapid onset, though
potentiation by genomic means via the classical AR cannot be excluded [38, 44, 46]. Inhibition of voltage-operated
calcium channels [VOCCs] and/or activation of potassium channels [KCs] on smooth muscle cells [SMCs] is believed
to be instrumental. Testosterone binds the same domain as nifedipine on VOCCs and thus promotes vasodilation by
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inactivating VOCCs. An alternate postulate is the activation of voltage-operated potassium channels by testosterone
and/or activation of calcium-activated potassium channels which give rise to hyperpolarisation, due to potassium efflux.
It has also been suggested that testosterone can inhibit calcium influx through store-operated calcium channels [SOCCs]
by  blunting  the  response  to  prostaglandin  F2α  [PGF2α].  In  terms  of  testosterone-mediated  genomic-dependent
mechanisms of vasodilation, it has been hypothesised that testosterone upregulates the expression of endothelial nitric
oxide synthase [eNOS], the enzyme responsible for synthesising nitric oxide [NO]. NO in turn brings about relaxation
of SMCs and subsequent vasodilatation by activating guanylate cyclase which produces cGMP, which in turn activates
cGMP-dependent protein kinase [PKG]. PKG phosphorylates and activates sarcoplasmic reticulum-ATPase [SERCA]
which results in augmentation of calcium levels in the sarcoplasmic reticulum [38].
2.4.3. Vasoconstriction
Aside from its suggested role in vasodilation, there are a few basic studies that seem to implicate testosterone in
vasoconstriction.  A study carried out  by Ammar et  al.  utilised male  rabbits  that  were administered either  25mg/kg
intramuscular testosterone weekly or no treatment, followed by the removal of the descending thoracic aorta. The vessel
was then either contracted with 5-hydroxytryptamine [5-HT] or dilated with sodium nitroprusside [SNP]. This study
showed that aortas from the testosterone-treated animals displayed a higher contractile percentage when exposed to 5-
HT and a lower relaxation percentage when exposed to SNP, suggesting that  testosterone limits  vasodilatation and
increases vasoconstriction. The aforementioned observations were statistically significant [44, 47].
A  preliminary  study  conducted  by  Ammar  et  al.  determined  the  effects  of  testosterone  on  isolated  as  well  as
perfused  coronary  arteries.  The  vasoconstricitve  actions  of  testosterone  were  apparent  [48].  It  is  believed  that
testosterone antagonises the vasodilatory effects of the vasodilator adenosine through increased vascular resistance and
competes with other vasodilators, though a concrete mechanism has not been proposed [44, 48].
2.4.4. Cardioprotection
One  study  investigated  the  role  of  testosterone  in  organ  reperfusion  following  vascular  occlusion.  Tsang  et  al.
isolated rat hearts from control, orchiectomised, and orchiectomised plus testosterone treatment [2mg/kg daily for 8
weeks]  groups.  The  coronary  arteries  were  pre-occluded  for  30  minutes  and  subsequently  reperfused  with  a
physiological solution for 120 minutes. Following isolation, it was observed that when compared to the control group,
MI infarct size was largest in the orchiectomised group, compared to the orchiectomised plus testosterone treatment
group.  This  finding suggests  that  testosterone may have a  role  in  vascular  reperfusion through which it  can impart
cardioprotection [44, 49].
2.4.5. Intima-Media Thickness
Intima media thickness [IMT] is a feature of atherosclerosis [50]. Demirbag et al. conducted a study in 42 male
patients without a history of atherosclerosis, who were referred for transoesophageal echocardiography [TOE]. IMT
was evaluated by TOE and testosterone levels quantified. The authors discovered an inverse relationship between total
testosterone and intima media thickness in the abdominal aorta independent of cardiovascular disease. The results of the
study therefore imply a preventative role of endogenous testosterone in coronary artery disease [51].
2.4.6. Gender Differences
The gender differences in testosterone physiology and plasma testosterone concentration in adolescent males and
females cannot be ignored. According to Mayo Medical Laboratories, the SHBG-bound testosterone reference range in
adolescent males and females at the pinnacle of pubertal development [Tanner stage V] suggests that there is a higher
percentage  of  SHBG-bound  testosterone  in  females  [18-144nmol/L  or  518-4149ng/dL]  compared  to  males
[10-57nmol/L or 288-1642ng/dL]. The physiological implication of this difference is yet to be unravelled. We propose a
reservoir-like  role  for  SHBG-bound  testosterone  to  replenish  circulating  oestradiol  in  females  via  the  actions  of
aromatase.
Some investigators believe that testosterone may be more harmful in females than in males [52 - 55]. This was
echoed by an animal study that utilised rat aortic rings from either atherosclerotic tunica intima or healthy tunica media,
as well as cultured rabbit SMCs. Female rat aortic rings treated with testosterone resulted in significant decreases in
prostacyclin [PGI2] synthesis whilst PGI2 synthesis in male rat aortic rings remained unchanged. It was suggested that
testosterone may induce atherogenic changes in females by modulating PGI2 synthesis [56].
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The beneficial effects of testosterone in males were also highlighted in another study where a group of testicular
feminised  mice  [Tfm]  and  littermates  were  fed  a  cholesterol-rich  diet  for  28  weeks.  They  were  then  treated  with
exogenous  testosterone  alone,  exogenous  testosterone  plus  the  oestrogen  receptor  α-antagonist  fulvestrant,  and
exogenous testosterone plus the aromatase inhibitor anastrazole. It was found that exogenous testosterone replacement
inhibited fatty streak formation in Tfm mice independent of the androgen receptor. Moreover, it was suggested that the
observed HDL-C increment may have been attributed to the conversion of testosterone to 17β-estradiol [57].
It is also important to consider how testosterone can potentiate the effects of CVD risk factors such as obesity in
males. It was found that obese men had lower levels of total and free testosterone, as well as SHGB-bound testosterone,
possibly due to upregulated aromatase activity which converts testosterone to oestradiol [58]. These individuals were
concluded to be at a greater risk of developing CVD and impotency when compared to the control population [58].
Since the SHBG-bound testosterone levels were low, one may argue that increasing levels of SHBG-bound testosterone
and concomitantly inhibiting aromatase may increase the circulating levels of free testosterone due to ‘testosterone
unloading’, which may help to reduce the risk of impotency and CVD. Therefore, comparing testosterone physiology in
males and females may help elucidate further mechanisms by which testosterone exerts its effects, as well emphasizing
the sex-specific pathophysiological mechanisms that implicate testosterone in CVD.
CONCLUSION
The scientific consensus from animal studies is vasodilatation, as studies supporting a role for vasoconstriction are
limited and conflicting.  The reported differences  may be attributed to  study design.  The testosterone concentration
utilised differed from study to study, as well  as vascular exposure time to testosterone. It  is  logical to propose that
depending on whether exposure to testosterone is acute or chronic, vasoconstriction or vasodilatation may be elicited to
maintain vasomotor tone and haemodynamic homeostasis. It is also worth stating that the animal studies were carried
out in different species and therefore species-dependent responses may have contributed to the observed differences.
More importantly, the limitation of basic science studies is that the animal physiology is not always representative of
human physiology, and may thus pose problems when research is translated from ‘bench to bedside’.
The beneficial effects of testosterone in certain scenarios have meant that efforts have been made to explore possible
avenues of increasing circulating testosterone concentrations. It was shown that endogenous insulin can help to increase
testosterone synthesis and inhibit testosterone binding to SHBG, thereby decreasing concentrations of SHBG-bound
testosterone and increasing free circulating testosterone [59]. Nevertheless, one has to consider the long-term effects of
chronic  insulin  administration  in  non-diabetics  as  well  as  the  issue  of  compliance,  since  insulin  can  only  be
administered intravenously due to risk of digestion. Furthermore, the study is limited due to a small study population
size.
There are unanswered questions on whether or not men over the age of 50 with coronary artery disease should also
be screened for hypogonadism. The difficulty lies in the fact that the role of hypotestosteronaemia in CVD whether
causal or consequential, has not been established. If indeed a causal relationship exists then chronic low dose TRT may
prove beneficial in clinical trials as this may improve cardiovascular outcome. It is also important to mention that no
uniform definition exists for hypogonadism and thus different investigators define it differently in terms of the reference
range. Introducing some standardization and consistency to androgen reference ranges that define hypogonadism and
hypotestosteronaemia will help to shed light in terms of study design and targeting the right population for investigation
and treatment [60 - 62].
All  in  all,  there  is  emerging  evidence  to  support  the  hypothesis  that  low  testosterone  levels  predict  a  poor
cardiovascular risk profile. Historically considered in the realms of reproductive biology and puberty, it is now clear
that the roles of testosterone extend beyond that anticipated. Although we are still far from unmasking the roles and
mechanisms of testosterone in the cardiac vasculature, one thing remains certain; that the future is bright. Testosterone
holds great promise; possibly the hormone that will revolutionise the field of cardiovascular physiology.
CONFLICT OF INTEREST
The authors confirm that this article content has no conflict of interest.
ACKNOWLEDGEMENTS
Declared none.
6   The Open Cardiovascular Medicine Journal, 2016, Volume 10 Tambo et al.
LIST OF ABBREVIATIONS
5-HT = 5-hydroxytryptamine
5α-DHT = 5α-dihydrotestosterone
ACS = Acute Coronary Syndromes
ACTH = Adrenocorticotrophin hormone
AR = Androgen receptor
AS = Androstenedione
CAD = Coronary artery disease
cGMP = cyclic-Guanosine Monophosphate
CHD = Coronary heart disease
CVD = Cardiovascular disease
DHEA-S = Dehydroepiandrosterone sulphate
eNOS = Endothelial nitric oxide synthase
GIT = Gastrointestinal tract
GnRH = Gonadotrophin-releasing hormone
HDL-C = High density lipoprotein-cholesterol
HPA = Hypothalamic-pituitary-adrenal axis
HPG = Hypothalamic-pituitary-gonadal
IMT = Intima media thickness
KCs = Potassium Channels
KHB = Kreb-Henseleit Bicarbonate
LAD = Left anterior descending coronary arteries
LH = Luteinising hormone
L-NAME = N-nitro-L-arginine methyl ester
MI = Infarction
NHS = National Health Service
NO = Nitric oxide
NOS = Nitric oxide synthase
OxLDL = Oxidised Low Density Lipoprotein
PGF2α = Prostaglandin F2α
RHD = Rheumatic heart disease
SERCA = Sacroplasmic reticulum-ATPase
SHBG = Sex Hormone Binding Globulin
SMCs = Smooth muscle cells
SNP = Sodium nitroprusside
SOCCs = Store-operated calcium channels
TOE = Transoesophageal echocardiography
TRT = Testosterone Replacement Therapy
VOCCs = Voltage-gated calcium channels
WHO = World Health Organisation
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